Viveve Medical Stock Current Valuation
VIVEDelisted Stock | USD 0.1 0.0005 0.53% |
Valuation analysis of Viveve Medical helps investors to measure Viveve Medical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Viveve Medical's price fluctuation is very steady at this time. Calculation of the real value of Viveve Medical is based on 3 months time horizon. Increasing Viveve Medical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Viveve pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Viveve Medical. Since Viveve Medical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Viveve Pink Sheet. However, Viveve Medical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 0.0955 | Real 0.0907 | Hype 0.1 | Naive 0.32 |
The real value of Viveve Pink Sheet, also known as its intrinsic value, is the underlying worth of Viveve Medical Company, which is reflected in its stock price. It is based on Viveve Medical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Viveve Medical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Viveve Medical helps investors to forecast how Viveve pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Viveve Medical more accurately as focusing exclusively on Viveve Medical's fundamentals will not take into account other important factors: Viveve Medical Company Current Valuation Analysis
Viveve Medical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Viveve Medical Current Valuation | 4.26 M |
Most of Viveve Medical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Viveve Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Viveve Medical has a Current Valuation of 4.26 M. This is 99.97% lower than that of the Health Care Equipment & Supplies sector and 99.97% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.97% higher than that of the company.
Viveve Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viveve Medical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Viveve Medical could also be used in its relative valuation, which is a method of valuing Viveve Medical by comparing valuation metrics of similar companies.Viveve Medical is currently under evaluation in current valuation category among its peers.
Viveve Fundamentals
Return On Equity | -2.11 | ||||
Return On Asset | -0.62 | ||||
Operating Margin | (3.10) % | ||||
Current Valuation | 4.26 M | ||||
Shares Outstanding | 10.72 M | ||||
Shares Owned By Institutions | 5.21 % | ||||
Number Of Shares Shorted | 374.24 K | ||||
Price To Earning | (2.59) X | ||||
Price To Book | 3.62 X | ||||
Price To Sales | 0.66 X | ||||
Revenue | 6.43 M | ||||
Gross Profit | 620 K | ||||
EBITDA | (19.89 M) | ||||
Net Income | (22.03 M) | ||||
Cash And Equivalents | 9.43 M | ||||
Cash Per Share | 0.88 X | ||||
Total Debt | 5.12 M | ||||
Debt To Equity | 1.12 % | ||||
Current Ratio | 1.32 X | ||||
Book Value Per Share | 0.11 X | ||||
Cash Flow From Operations | (12.88 M) | ||||
Short Ratio | 4.15 X | ||||
Earnings Per Share | (2.55) X | ||||
Price To Earnings To Growth | (0.13) X | ||||
Target Price | 3.1 | ||||
Number Of Employees | 47 | ||||
Beta | 0.37 | ||||
Market Capitalization | 1.08 M | ||||
Total Asset | 25.91 M | ||||
Retained Earnings | (68.62 M) | ||||
Working Capital | 13.21 M | ||||
Current Asset | 18.53 M | ||||
Current Liabilities | 5.32 M | ||||
Z Score | -2.8 | ||||
Net Asset | 25.91 M |
About Viveve Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viveve Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viveve Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viveve Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Viveve Pink Sheet
If you are still planning to invest in Viveve Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viveve Medical's history and understand the potential risks before investing.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bonds Directory Find actively traded corporate debentures issued by US companies |